OSU A&M Board of Regents accepts President Kayse Shrum's resignation
STILLWATER, Okla. (KFOR) – The Oklahoma State University A&M Board of Regents has accepted the resignation of Dr. Kayse Shrum.
The Board released the following statement on Wednesday, February 5:
'We extend our deepest gratitude to Dr. Shrum for her dedicated leadership, unwavering commitment to students, and significant contributions to the OSU System.
'Dr. Shrum has led with passion and vision, championing key initiatives in academics, research and innovation while advancing OSU's land-grant mission. During her tenure, Oklahoma State University has experienced record enrollment, student retention rates, research funding, and philanthropic support setting the stage for a bright future. From the outset of her presidency, she was thrust into a critical role of navigating the disruption within the Big 12 Conference. Dr. Shrum worked tirelessly to help stabilize the league and protect OSU's athletic programs, ensuring the university remained competitive on the national stage.
'Under her leadership, OSU has strengthened its impact in health care and STEM education while expanding access to higher education – ensuring that students of all backgrounds can find opportunities and a home at OSU.
'The Board will begin the process of identifying the next leader for Oklahoma State University and will provide updates as that process moves forward. In the meantime, we are committed to ensuring a smooth transition and maintaining the momentum of OSU's mission to serve the state of Oklahoma and beyond.
'We thank Dr. Shrum for her service and wish her the very best in her future endeavors.'
LOCAL NEWS: Dr. Kayse Shrum expected to resign as OSU President
Dr. Shrum has been on the job for less than four years.
During her tenure, Dr. Shrum led the way with the challenges of the COVID-19 pandemic and conference realignment, all while bringing new initiatives to the university: the Hamm Institute for American Energy, the Oklahoma Aerospace Institute for Research and Education, the Human Performance and Nutrition Research Institute, and the OSU Student Farm.
OSU has also set multiple enrollment records under Dr. Shrum, including the highest undergraduate enrollment, the largest first-time freshman class, and becoming the state's largest university system.
The university also set records for non-residents, Honors College, Spears School of Business, Native American, first-generation, online, and new graduate students.
According to the Board of Regents, the resignation is effective February 3.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities. 'As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee,' said Lynn Seely, MD, Lyell's President and Chief Executive Officer. 'Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.' 'The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314,' said Rick Klausner, MD, Chairman of the Lyell Board of Directors. 'I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.' Mark J. Bachleda, PharmD, MBA appointed independent member of the Board of Directors Dr. Bachleda is currently the Chief Executive Officer and a member of the Board of Directors of Eyconis, Inc., a biopharmaceutical company focused on developing therapeutics for eye diseases. He has served in executive leadership roles at Amgen, Juno Therapeutics, and Bristol Myers Squibb (BMS), and, most recently, he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President & U.S. Business Unit Head of the CAR T-cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS. Prior to this, he was Vice President, Sales & Account Management at Juno when it was acquired by Celgene. His experience includes a 15-year career at Amgen in the U.S. and international roles of increasing responsibility up to Country President & General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc., and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his PharmD degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley. David Shook, MD appointed Chief Medical Officer Dr. Shook is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook was Chief Medical Officer and Head of Research and Development at Nkarta where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth and was Fellowship Director and a Faculty Member at St. Jude Children's Research Hospital. While at St. Jude, he conducted multiple first-in-human cell therapy trials, as well as research in the laboratory of Dario Campana, MD, PhD where he co-developed the membrane bound form of interleukin-15. He earned an MD from The Johns Hopkins University School of Medicine and a BS from Purdue University. Mark Meltz, JD appointed General Counsel and Corporate Secretary Mr. Meltz is an accomplished legal and business executive with more than two decades of experience leading and advising life sciences, technology and emerging growth companies. Prior to joining Lyell, Mr. Meltz was Chief Operating Officer and General Counsel of Kinnate Biopharma Inc., a clinical stage precision oncology company, through its sale to XOMA Corporation. Before Kinnate, he was Senior Vice President and General Counsel of Audentes Therapeutics through its sale to Astellas Pharma. Mr. Meltz also was previously Executive Vice President and Chief Business Development and Legal Officer at PaxVax through its sale to Emergent BioSolutions. Earlier in his career, Mr. Meltz was Associate General Counsel at Biogen and Head of Legal for North America at Novartis in its Vaccines & Diagnostics division. Mr. Meltz has supported multiple commercial launches at PaxVax, Biogen and Novartis. He earned a BA with Departmental Honors in Psychology from Yale University and a JD, Magna Cum Laude, from Boston College Law School. Jarrad Aguirre, MD, MBA appointed Senior Vice President, Medical Affairs Dr. Aguirre joined Lyell as Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an MD and an MBA from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a BS in Biology from Yale University. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of the Company's additions to its leadership team and Board of Directors, including the anticipated benefits of expanded strength of the Company's clinical and commercial capabilities; the continued clinical progress and anticipated commercial launch of the LYL314 trials; Lyell's anticipated progress, business plans, business strategy and clinical trials; Lyell's advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell's product candidates; and other statements that are not historical fact. These statements are based on Lyell's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the ability to retain the continued service of its key personnel; the complexity of manufacturing cellular therapies, which subjects Lyell to a multitude of manufacturing risks, any of which could substantially increase our costs, delay Lyell's programs or limit supply of Lyell's product candidates; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell's ability to initiate or progress clinical trials on the anticipated timelines, if at all; Lyell's limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell's product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell's product candidates; the significant uncertainty associated with Lyell's product candidates ever receiving any regulatory approvals; Lyell's ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell's strategic plans for its business and product candidates; the sufficiency of Lyell's capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading 'Risk Factors' in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Arkansas ranks 45th for child well-being in national report, despite modest gains
LITTLE ROCK, Ark. – Arkansas ranks 45th in the nation for overall child well-being, according to the 2025 KIDS COUNT Data Book released Monday by the Annie E. Casey Foundation. The annual report evaluates how children are doing across all 50 states in four areas: economic well-being, education, health, and family and community. 6-year-old Dennis Martin still missing after disappearing in Smokies in 1969 Though Arkansas has made some gains since the COVID-19 pandemic, the state continues to fall behind on most indicators compared to national averages. One area of progress is child poverty. The number of Arkansas children living in poverty has dropped by 7,000 since 2019. Still, 21% of the state's children remain in poverty, which is higher than the national rate of 16%. 'This report shows that while there has been some improvement, too many of our children are still being left behind,' said Keesa Smith-Brantley, executive director of Arkansas Advocates for Children and Families. 'We can't be satisfied with small gains when the overall trends remain troubling.' Racial disparities remain a serious issue. Officials said Black children in Arkansas face a poverty rate of 43%. Children of two or more races have a poverty rate of 21%, while 19% of Hispanic or Latino children live in poverty. Non-Hispanic White children have the lowest poverty rate at 15%. Ohio girl with brain injury from flu complications returns home In addition to being ranked 44th for child poverty, Arkansas is in the bottom 10 states on the following indicators: Teens ages 16-19 not attending school and not working 8th graders below proficient on math level Low-birthweight babies Child and teen deaths Teens ages 10-17 who are overweight or obese Children in single-parent families Children living in high-poverty areas Teen birth rate 'If you look at the data, teens are where we're falling further behind,' Smith-Brantley said. 'We're seeing more teens out of school and unemployed, and more who are overweight or obese. These are outcomes tied directly to the decisions our leaders are or aren't making.' For more information, visit Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
